|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2显示文摘Dear Editor To date,tens of millions of people have been infected with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),causing the outbreak of the respiratory disease named the coronavirus disease 2019(COVID-19).As a newly emerged member of the coronavirus family,SARS-CoV-2 is an enveloped positive-strand RNA virus,which has probably the largest genome(approximately 30 kb)among all RNA viruses.The nucleocapsid(N)protein of SARS-CoV-2 is mainly responsible for recognizing and wrapping viral RNA into helically symmetric structures(Malik,2020). | Dan Zhao Weifan Xu Xiaofan Zhang Xiaoting Wang Yiyue Ge Enming Yuan Yuanpeng Xiong Shenyang Wu Shuya Li Nian Wu Tingzhong Tian Xiaolong Feng Hantao Shu Peng Lang Jingxin Li Fengcai Zhu Xiaokun Shen Haitao Li Pilong Li Jianyang Zeng | 2021 | Protein & Cell2021，12，9： | 1 |
| 2 | An algorithm of global optimization for solving layout problems显示文摘 | Feng Enming Wang Xilu Wang Xiumei Teng Hongfei | 1999 | European Journal of operational research1999，114，： | 1 |
| 3 | An algorithm of global optimization for solving layout problems显示文摘 | Xilu Wang Xiumei Wang | 1999 | European Journal of Operational Research1999，，114： | 1 |
| 4 | An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19显示文摘The global spread of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)requires an urgent need to find effective therapeutics for the treatment of coronavirus disease 2019(COVID-19).In this study,we developed an integrative drug repositioning framework,which fully takes advantage of machine learning and statistical analysis approaches to systematically integrate and mine large-scale knowledge graph,literature and transcriptome data to discover the potential drug candidates against SARS-CoV-2.Our in silico screening followed by wet-lab validation indicated that a poly-ADP-ribose polymerase 1(PARP1)inhibitor,CVL218,currently in Phase I clinical trial,may be repurposed to treat COVID-19.Our in vitro assays revealed that CVL218 can exhibit effective inhibitory activity against SARS-CoV-2 replication without obvious cytopathic effect.In addition,we showed that CVL218 can interact with the nucleocapsid(N)protein of SARS-CoV-2 and is able to suppress the LPS-induced production of several inflammatory cytokines that are highly relevant to the prevention of immunopathology induced by SARS-CoV-2 infection. | Yiyue Ge Tingzhong Tian Suling Huang Fangping Wan Jingxin Li Shuya Li Xiaoting Wang Hui Yang Lixiang Hong Nian Wu Enming Yuan Yunan Luo Lili Cheng Chengliang Hu Yipin Lei Hantao Shu Xiaolong Feng Ziyuan Jiang Yunfu Wu Ying Chi Xiling Guo Lunbiao Cui Liang Xiao Zeng Li Chunhao Yang Zehong Miao Ligong Chen Haitao Li Hainian Zeng Dan Zhao Fengcai Zhu Xiaokun Shen Jianyang Zeng | 2021 | Signal Transduction and Targeted Therapy2021，6，5： | 0 |
| 5 | BCL9 regulates CD226 and CD96 checkpoints in CD8^(+)T cells to improve PD-1 response in cancer显示文摘To date,the overall response rate of PD-1 blockade remains unsatisfactory,partially due to limited understanding of tumor immune microenvironment(TIME).B-cell lymphoma 9(BCL9),a key transcription co-activator of the Wnt pathway,is highly expressed in cancers.By genetic depletion and pharmacological inhibition of BCL9 in tumors,we found that BCL9 suppression reduced tumor growth. | Mei Feng Zhongen Wu Yan Zhou Zhuang Wei Enming Tian Shenglin Mei Yuanyuan Zhu Chenglong Liu Fenglian He Huiyu Li Cao Xie Joy Jin Jibin Dong Dehua Yang Ker Yu Junbin Qian Diether Lambrechts Ming-Wei Wang Di Zhu | 2021 | Signal Transduction and Targeted Therapy2021，6，9： | 0 |
| 6 | Introduction of Magnet Division's Key Work in 2019显示文摘Last year,the MTG(Magnet Technology Group)undertaken the magnet development formany accelerators such as High Intensity heavy ion Accelerator Facility(HIAF),China initiative Accelerator Driven System(CiADS),Space.Environment Simulation and Research Infrastructure(SESRI). | Yao Qinggao Wu Wei Yang Wenjie Ni Dongsheng Zhang Xiang Zhang Jingjing Mei Enming Feng Wentian | 2019 | IMP & HIRFL Annual Report2019，，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员